The performance of companies tied to the drug's legacy presents a complex investment landscape. While the initial surge generated substantial gains, generic copies have significantly eroded sales . Investing in associated pharmaceutical companies now requires a thorough assessment of intellectual property rights , evolving patient trends , and the